BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scandinavian Journal of Gastroenterology 2010;45:389-94. [DOI: 10.3109/00365520903477348] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Gould E, Clements C, Reed A, Giori L, Steiner JM, Lidbury JA, Suchodolski JS, Brand M, Moyers T, Emery L, Tolbert MK. A Prospective, Placebo-Controlled Pilot Evaluation of the Effect of Omeprazole on Serum Calcium, Magnesium, Cobalamin, Gastrin Concentrations, and Bone in Cats. J Vet Intern Med 2016;30:779-86. [PMID: 27062346 DOI: 10.1111/jvim.13932] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
2 Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56:931-950. [PMID: 21365243 DOI: 10.1007/s10620-010-1560-3] [Cited by in Crossref: 187] [Cited by in F6Publishing: 164] [Article Influence: 18.7] [Reference Citation Analysis]
3 Ariel H, Cooke JP. Cardiovascular Risk of Proton Pump Inhibitors. Methodist Debakey Cardiovasc J 2019;15:214-9. [PMID: 31687101 DOI: 10.14797/mdcj-15-3-214] [Reference Citation Analysis]
4 Niv Y. Gradual cessation of proton pump inhibitor (PPI) treatment may prevent rebound acid secretion, measured by the alkaline tide method, in dyspepsia and reflux patients. Med Hypotheses. 2011;77:451-452. [PMID: 21723045 DOI: 10.1016/j.mehy.2011.06.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
5 Golly E, Odunayo A, Daves M, Vose J, Price J, Hecht S, Steiner JM, Hillsman S, Tolbert MK. The frequency of oral famotidine administration influences its effect on gastric pH in cats over time. J Vet Intern Med 2019;33:544-50. [PMID: 30746763 DOI: 10.1111/jvim.15430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
6 Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol 2012;28:615-20. [PMID: 23010681 DOI: 10.1097/MOG.0b013e328358d5b9] [Cited by in Crossref: 85] [Cited by in F6Publishing: 36] [Article Influence: 10.6] [Reference Citation Analysis]
7 Lødrup AB, Reimer C, Bytzer P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scand J Gastroenterol. 2013;48:515-522. [PMID: 23311977 DOI: 10.3109/00365521.2012.746395] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
8 McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010;26:624-31. [PMID: 20802330 DOI: 10.1097/MOG.0b013e32833ea9d9] [Cited by in Crossref: 90] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
9 Jianu CS, Fossmark R, Syversen U, Hauso Ø, Fykse V, Waldum HL. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scand J Gastroenterol. 2011;46:456-463. [PMID: 21133821 DOI: 10.3109/00365521.2010.539255] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
10 Lerotić I, Baršić N, Stojsavljević S, Duvnjak M. Acid Inhibition and the Acid Rebound Effect. Dig Dis 2011;29:482-6. [DOI: 10.1159/000331514] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
11 Sukhovershin RA, Cooke JP. How May Proton Pump Inhibitors Impair Cardiovascular Health? Am J Cardiovasc Drugs 2016;16:153-61. [PMID: 26817947 DOI: 10.1007/s40256-016-0160-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
12 Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol 2018;123:114-21. [PMID: 29658189 DOI: 10.1111/bcpt.13023] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 13.3] [Reference Citation Analysis]
13 Rice KS, Dickson G, Lane M, Crawford J, Chung SK, Rees MI, Shelling AN, Love DR, Skinner JR. Elevated serum gastrin levels in Jervell and Lange-Nielsen syndrome: A marker of severe KCNQ1 dysfunction? Heart Rhythm. 2011;8:551-554. [PMID: 21118729 DOI: 10.1016/j.hrthm.2010.11.039] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
14 Ojeaburu JV, Ito T, Crafa P, Bordi C, Jensen RT. Mechanism of acid hypersecretion post curative gastrinoma resection. Dig Dis Sci 2011;56:139-54. [PMID: 20725788 DOI: 10.1007/s10620-010-1234-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
15 Poudel A, Ballokova A, Hubbard RE, Gray LC, Mitchell CA, Nissen LM, Scott IA. Algorithm of medication review in frail older people: Focus on minimizing the use of high-risk medications. Geriatr Gerontol Int 2016;16:1002-13. [PMID: 26338275 DOI: 10.1111/ggi.12589] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
16 Schubert ML. Gastric secretion. Curr Opin Gastroenterol. 2010;26:598-603. [PMID: 20838342 DOI: 10.1097/mog.0b013e32833f2010] [Cited by in Crossref: 48] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
17 Gelfond D, Ma C, Semler J, Borowitz D. Intestinal pH and Gastrointestinal Transit Profiles in Cystic Fibrosis Patients Measured by Wireless Motility Capsule. Dig Dis Sci 2013;58:2275-81. [DOI: 10.1007/s10620-012-2209-1] [Cited by in Crossref: 86] [Cited by in F6Publishing: 74] [Article Influence: 9.6] [Reference Citation Analysis]
18 Helgadóttir H, Metz DC, Lund SH, Gizurarson S, Jacobsen EI, Asgeirsdóttir GA, Yngadóttir Y, Björnsson ES. Study of Gender Differences in Proton Pump Inhibitor Dose Requirements for GERD: A Double-Blind Randomized Trial. Journal of Clinical Gastroenterology 2017;51:486-93. [DOI: 10.1097/mcg.0000000000000542] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Rehfeld JF. Gastrointestinal hormone research – with a Scandinavian annotation. Scandinavian Journal of Gastroenterology 2015;50:668-79. [DOI: 10.3109/00365521.2015.1025831] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
20 Reeve E, Andrews JM, Wiese MD, Hendrix I, Roberts MS, Shakib S. Feasibility of a patient-centered deprescribing process to reduce inappropriate use of proton pump inhibitors. Ann Pharmacother. 2015;49:29-38. [PMID: 25385826 DOI: 10.1177/1060028014558290] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
21 Teixeira MZ. Rebound acid hypersecretion after withdrawal of gastric acid suppressing drugs: new evidence of similitude. Homeopathy. 2011;100:148-156. [PMID: 21784332 DOI: 10.1016/j.homp.2011.05.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
22 Lee L, Ramos-Alvarez I, Ito T, Jensen RT. Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome. Int J Mol Sci 2019;20:E5128. [PMID: 31623145 DOI: 10.3390/ijms20205128] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
23 Sarnaik MK, Modi S, Pisipati Y, Vaidya S, Syed Gaggatur N, Sange AH, Srinivas N, Sange I. Proton Pump Inhibitors: Exploring Cardiovascular Complications and Prescription Protocol. Cureus 2021;13:e16744. [PMID: 34354892 DOI: 10.7759/cureus.16744] [Reference Citation Analysis]
24 Metz DC, Pilmer BL, Han C, Perez MC. Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data. Am J Gastroenterol 2011;106:1953-60. [PMID: 21844923 DOI: 10.1038/ajg.2011.220] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
25 Hálfdánarson ÓÖ, Pottegård A, Björnsson ES, Lund SH, Ogmundsdottir MH, Steingrímsson E, Ogmundsdottir HM, Zoega H. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol 2018;11:1756284818777943. [PMID: 29872455 DOI: 10.1177/1756284818777943] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 13.3] [Reference Citation Analysis]
26 Helgadóttir H, Lund SH, Gizurarson S, Waldum H, Björnsson ES. Pharmacokinetics of single and repeated oral doses of esomeprazole and gastrin elevation in healthy males and females. Scand J Gastroenterol 2021;56:128-36. [PMID: 33327801 DOI: 10.1080/00365521.2020.1859610] [Reference Citation Analysis]
27 Helgadóttir H, Lund SH, Gizurarson S, Metz DC, Björnsson ES. Predictors of Gastrin Elevation Following Proton Pump Inhibitor Therapy. J Clin Gastroenterol 2020;54:227-34. [PMID: 30994520 DOI: 10.1097/MCG.0000000000001200] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
28 Peura D, Le Moigne A, Pollack C, Nagy P, Lind T. A 14-day regimen of esomeprazole 20 mg/day for frequent heartburn: durability of effects, symptomatic rebound, and treatment satisfaction. Postgrad Med 2016;128:577-83. [PMID: 27331882 DOI: 10.1080/00325481.2016.1203236] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
29 Helgadottir H, Bjornsson ES. Problems Associated with Deprescribing of Proton Pump Inhibitors. Int J Mol Sci 2019;20:E5469. [PMID: 31684070 DOI: 10.3390/ijms20215469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
30 Teixeira MZ. Rebound effect of modern drugs: serious adverse event unknown by health professionals. Rev Assoc Med Bras (1992) 2013;59:629-38. [PMID: 24211013 DOI: 10.1016/j.ramb.2013.05.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
31 Juul-Hansen P, Rydning A. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem? Scand J Gastroenterol. 2011;46:398-405. [PMID: 21142586 DOI: 10.3109/00365521.2010.537684] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
32 Waldum HL, Hauso Ø, Fossmark R. The regulation of gastric acid secretion - clinical perspectives. Acta Physiol (Oxf). 2014;210:239-256. [PMID: 24279703 DOI: 10.1111/apha.12208] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
33 Bajaj JS, Cox IJ, Betrapally NS, Heuman DM, Schubert ML, Ratneswaran M, Hylemon PB, White MB, Daita K, Noble NA, Sikaroodi M, Williams R, Crossey MM, Taylor-Robinson SD, Gillevet PM. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol. 2014;307:G951-G957. [PMID: 25258407 DOI: 10.1152/ajpgi.00268.2014] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 14.6] [Reference Citation Analysis]
34 Helgadóttir H, Metz DC, Yang Y, Rhim AD, Björnsson ES. The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin. Digestive and Liver Disease 2014;46:125-30. [DOI: 10.1016/j.dld.2013.09.021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]